Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (50)

I-03

Integrating a tumour Growth inhibition Model within a Physiologically-Based Pharmacokinetic Model to predict Erlotinib tumour concentrations in Mice

Wednesday 09:50-11:15

I-04Anson Abraham

Lack of pre-clinical target pharmacology: How to predict first-in-human trial dose(s) and inform clinical trial design?

Wednesday 09:50-11:15

I-07Oliver Ackaert

Characterizing exposure of apalutamide and its active metabolite, N-desmethyl-apalutamide, in healthy and castration-resistant prostate cancer subjects

Wednesday 09:50-11:15

I-10Maurice Ahsman

A mechanism-based population K-PD model for long-term testosterone inhibition in prostate cancer patients under intermittent androgen deprivation therapy

Wednesday 09:50-11:15

I-18Usman Arshad

A semi-mechanistic pharmacokinetic-pharmacodynamic model of 5-fluorouracil continuous infusion in gastrointestinal cancer patients

Wednesday 09:50-11:15

I-25LE Ba Hai

Population pharmacokinetic model of sorafenib and application to a case report

Wednesday 09:50-11:15

I-38Aliénor Bergès

Importance of Quantifying Neutropenia Risk Factors in Phase I Solid Malignancy Dose Finding; A Simulation Case

Wednesday 09:50-11:15

I-43Bruno Bieth

Optimal Scheduling of Bevacizumab and Pemetrexed/Cisplatin Dosing in Non-Small Cell Lung Cancer

Wednesday 09:50-11:15

I-47Elisa Borella

Development of a Target-Mediated Drug Disposition Model for the Prediction of Target Occupancy of MEN1112, an Anti Bst1/CD157 Humanized Antibody for the Treatment of Acute Myeloid Leukaemia

Wednesday 09:50-11:15

I-51Muriel Boulton

What is the proportion of abiraterone acetate effect on radiographic Progression-Free-Survival (rPFS) explained by Prostate‐Specific Antigen (PSA) kinetics in metastatic castration-resistant prostate cancer (mCRPC)?

Wednesday 09:50-11:15

I-55Núria Buil Bruna

Can monocyte counts predict future drug-induced neutropenia toxicities?

Wednesday 09:50-11:15

I-60Tim Cardilin

Tumor Static Exposure for anticancer combinations in early drug discovery

Wednesday 09:50-11:15

I-71Viji Chelliah

Mechanistic models of cancer-immune cycle and immunotherapies

Wednesday 09:50-11:15

I-74Siri Kalyan Chirumamilla

Application of physiologically-based pharmacokinetic model to mechanistically predict increased tumour uptake of paclitaxel in cancer patients

Wednesday 09:50-11:15

I-86Oleg Demin Jr

Investigation of dose response behavior of bispecific T-cell engaging antibodies using quantitative systems pharmacology modeling

Wednesday 09:50-11:15

I-87Laure Deyme

Optimizing FOLFIRINOX regimen in pancreatic adenocarcinoma using a 5FU-PKPD model of neutropenia including G-CSF rescue

Wednesday 09:50-11:15

II-05Sofiene Laarif

Quantitative modeling of inter-lesion and inter-organ variability of tumor size

Wednesday 15:10-16:40

II-24Aurelie Lombard

Tumour size measurements: impact of inter-operator variability on model-based drug effect evaluation

Wednesday 15:10-16:40

II-31Sreenath M Krishnan

A combined population kinetic-pharmacodynamic-overall survival model for docetaxel and paclitaxel in the treatment of HER2–negative metastatic breast cancer patients

Wednesday 15:10-16:40

II-41Paolo Mazzei

Prospective Evaluation of a Model-Based approach to select Phase 1 Dosing Regimen for MEN1309/OBT076, a novel antibody drug conjugate (ADC) targeting Ly75 antigen for the treatment of CD205-positive metastatic solid tumours and Non-Hodgkin lymphoma

Wednesday 15:10-16:40

II-46Matilde Merino-Sanjuán

Impact of ABC gene single nucleotide polymorphisms in population pharmacokinetic of capecitabine and its metabolites 5′-deoxy-5-fluorouridine (5′-DFUR) 5-fluorouracil (5-FU) in patients with colorectal cancer

Wednesday 15:10-16:40

II-53Anna Mc Laughlin

Model-informed precision dosing for tamoxifen therapy in breast cancer patients: Comparison of different target attainment metrics

Wednesday 15:10-16:40

II-58Ida Neldemo

The tumor time-course predicts the overall survival in non-small cell lung cancer patients treated with atezolizumab in a large Phase I study: an evaluation of using different censoring times

Wednesday 15:10-16:40

II-60Laurent Nguyen

Pharmacokinetic time-dependency and covariates modelling of Isatuximab monoclonal antibody in multiple myeloma patients: analysis from pooled phase I/II & phase III studies

Wednesday 15:10-16:40

II-66Fernando Ortega

Developing a head and neck cancer model to assess the effect of radiotherapy on tumour growth inhibition and regrowth

Wednesday 15:10-16:40

II-71Christophe Passot

A kinetic-pharmacodynamic model of palbociclib reveals an influence of body weight on neutropenia onset.

Wednesday 15:10-16:40

II-73Carlos Perez-Ruixo

Exposure-response relationships of the efficacy and safety of apalutamide (APA) in men with non-metastatic castration-resistant prostate cancer (nmCRPC)

Wednesday 15:10-16:40

II-76Chiara Piana

Development of a translational pharmacokinetic-biomarker-efficacy model in mouse to support dose recommendation in human

Wednesday 15:10-16:40

II-83Alicja Puszkiel

Population pharmacokinetic analysis of tamoxifen and its six metabolites in breast cancer patients: Quantification of the impact of genetic polymorphisms and co-medications on tamoxifen metabolism

Wednesday 15:10-16:40

III-30Mark Stroh

Translation and Mechanistic Corroboration of the Preliminary Clinical Pharmacokinetics and Pharmacodynamics of a Masked, Tumor‑Activated anti-PD-L1 Antibody with Systems Pharmacology

Thursday 09:55-11:20

III-46Iñaki F. Trocóniz

A modelling platform for onco-immunological drugs in early drug development

Thursday 09:55-11:20

III-52Cristina Vaghi

Population modeling of tumor growth curves, the reduced Gompertz model and prediction of the age of a tumor

Thursday 09:55-11:20

III-54Arthur Van De Vyver

in vitro PK/PD modeling of immunological synapse-based tumor cell killing and immune activation to predict in vitro efficacy of T-Cell Bispecifics.

Thursday 09:55-11:20

III-56Jan-Stefan van der Walt

A Population Pharmacokinetic Analysis to Explore the Effect of Hepatic Impairment on Abemaciclib Pharmacokinetics

Thursday 09:55-11:20

III-59Filippo Venezia

Preclinical Pharmacokinetic/Pharmacodynamic modeling to evaluate combination efficacy and the modification effect of oncology compounds with anti-angiogenic drugs (Sunitinib, Axitinib)

Thursday 09:55-11:20

III-75Mélanie Wilbaux

Projecting MIW815 (ADU-S100) human tumor PK after intra-tumoral injection using a translational modeling approach combining pre-clinical and clinical data

Thursday 09:55-11:20

III-77Francis Williams Ojara

Time-to-event analysis framework to evaluate the impact of paclitaxel exposure on peripheral neuropathy in patients with advanced non-small cell lung cancer receiving first-line chemotherapy

Thursday 09:55-11:20

III-83Anyue Yin

Population pharmacokinetics and pharmacogenetics analysis of mitotane in adrenocortical carcinoma patients towards individualized dosing

Thursday 09:55-11:20

III-85Sirin Yonucu

Explaining inter-species differences to anti-PDL1 cancer immunotherapy using a translational quantitative systems pharmacology approach

Thursday 09:55-11:20

III-86Jurij Aguiar Zdovc

Population pharmacokinetic modeling of cisplatin in patients with small cell lung cancer using informative priors

Thursday 09:55-11:20

IV-02Anne-Gaelle Dosne

Exposure-response analysis of erdafitinib and pharmacodynamic-guided dose individualization in patients with locally advanced or metastatic urothelial carcinoma

Thursday 15:25-16:50

IV-23Fanny Gallais

Population pharmacokinetics of ibrutinib and its dihydrodiol metabolite in patients with lymphoid malignancies

Thursday 15:25-16:50

IV-26Sergey Gavrilov

Longitudinal assessment of tumor size and neutrophil count in multivariate joint models are more predictive of survival than their baseline values in patients with non-small cell lung cancer

Thursday 15:25-16:50

IV-34Katharina Martha Götz

Predictive Systems Medicine Modelling of Myelosuppression and Recovery of Hematopoietic Cells among Adult Patients with Hematopoietic Cell Transplantation

Thursday 15:25-16:50

IV-37Ana-Marija Grisic

Semimechanistic clearance models of oncology monoclonal antibodies and impact of study design: cetuximab as a case study

Thursday 15:25-16:50

IV-45Farina Hellmann

Population pharmacokinetic modelling in Ewing sarcoma patients focussing on etoposide as an example

Thursday 15:25-16:50

IV-57Hiroyuki Iida

Modelling the biomarker-driven tumour growth inhibition by a novel pan-Trk inhibitor ONO-7579 in xenografted mice

Thursday 15:25-16:50

IV-68Felix Jost

Application of a feedback optimal control algorithm to a population pharmacokinetic-pharmacodynamic model of cytarabine-derived and lenograstim-reduced myelosuppression in acute myeloid leukemia

Thursday 15:25-16:50

IV-76Hidefumi Kasai

Tumor Response Index (TRI): model-based prediction of tumor response and survival in metastatic colorectal cancer patients treated by mFOLFOX6 with bevacizumab

Thursday 15:25-16:50

IV-85Lena Klopp-Schulze

Exposure-response analyses of the bifunctional fusion protein bintrafusp alfa (M7824) in early drug development

Thursday 15:25-16:50